Search Results

Merck joins a growing list of companies targeting lipoprotein(a), high levels of which are associated with an elevated risk of adverse cardiovascular outcomes.

Altimmune, Inc., a clinical-stage biopharmaceutical company, presented data on the effect of pemvidutide, its GLP-1/glucagon dual receptor agonist candidate in development for obesity and metabolic dysfunction-associated steatohepatitis, on cardioinflammatory lipids at the American Diabetes Association’s 84th Scientific Sessions.

As a leader in the field of research-based cardiorenal metabolic health education, CMHC is proud to partner with like-minded organizations such as the National Lipid Association, which offers its education-focused agenda to a wide number of lipid specialists representing all areas of the U.S.

The global lipid nanoparticles market revenue reached US$ 820.51 million in 2023 and is estimated to reach a market valuation of US$ 2,387.98 million by 2032, growing at a Compound Annual Growth Rate (CAGR) of 12.6% during the forecast period from 2024 to 2032.

Baxter International Inc. (NYSE:BAX), a global leader in nutrition therapy, today announced U.S. FDA approval of an expanded indication for Clinolipid (Lipid Injectable Emulsion) to be used in pediatric patients, including preterm and term neonates.